Asarfi Hospital to Review September Quarter Results November 13

Asarfi Hospital Limited is scheduled to consider its unaudited financial results for the quarter ended September 30, 2026, at a board meeting on November 13, 2026, following Q1 FY27 revenue of ₹48.10 crore and profit of ₹4.27 crore. The disclosure matters because it will provide the next reported update on the hospital operator's financial performance.

What will Asarfi Hospital's board consider on November 13?

Asarfi Hospital's board is scheduled to consider, approve and take on record the unaudited financial results for the quarter ended September 30, 2026. The company informed BSE of the meeting on November 6, 2026, under its board-meeting intimation.

The agenda also includes a limited review report from statutory auditors R. K. Thakkar & Co., Chartered Accountants, according to the available company news. A limited review accompanies interim financial statements and is distinct from the full audit process used for annual accounts.

The supplied disclosures do not provide September-quarter revenue, profit, expenses, or earnings per share. Although some material states that results were declared on November 13, no numerical Q2 FY27 outcome is included. Investors therefore need to rely on the formal results filing for the reported quarterly figures.

What did Asarfi Hospital report in the previous quarter?

Asarfi Hospital reported Q1 FY27 revenue of ₹48.10 crore and profit of ₹4.27 crore in the information provided. These figures set the immediate comparison point for the September-quarter disclosure.

A separate Q1 FY27 summary in the provided material puts revenue at ₹47.53 crore, up 5.06% quarter-on-quarter from ₹45.24 crore and 33.21% year-on-year. The difference between ₹48.10 crore and ₹47.53 crore is present in the source material, and the company filing should be treated as the relevant reference for final reported figures.

The quarterly financial table shows revenue of 48 and net profit of 4 for June 2026, though the table does not state its unit in the header. It also records EBITDA of 10, operating profit margin of 20%, and EPS of ₹2.17 for that quarter.

How has Asarfi Hospital's financial performance developed?

Asarfi Hospital's quarterly table indicates that revenue rose from 21 in December 2023 to 48 in June 2026. Over the same period, the table shows net profit improving from a marginal loss in December 2023 to 4 in June 2026.

The figures also show some variability in operating performance. EBITDA was listed at 12 in December 2025, fell to 8 in March 2026, and recovered to 10 in June 2026. Operating profit margin was 22% in December 2025, 17% in March 2026, and 20% in June 2026.

For FY26, Asarfi Hospital approved audited standalone and consolidated financial results, and the supplied information says the auditors issued an unmodified opinion. This indicates that the annual financial statements were approved without a modified audit conclusion, based on the stated disclosure.

What corporate actions have shareholders approved?

Asarfi Hospital shareholders approved the FY26 financial statements, a director reappointment, and the company's migration to the BSE Main Board at its 21st annual general meeting on September 18, 2026. The meeting also approved authorisation for an NSE listing, according to the AGM-related information provided.

The Main Board migration and NSE listing authorisation are governance and market-access steps rather than operating results. Their financial effect cannot be assessed from the available disclosures, but they are relevant context for investors tracking the company's corporate developments.

The shareholding information supplied also identifies India-Ahead Venture Fund with a 1.5% holding. No change in this holding, promoter ownership, or other investor holdings is disclosed in the material.

Why does the September-quarter filing matter to investors?

Asarfi Hospital's September-quarter filing matters because it will show whether the revenue level reported for Q1 FY27 was sustained in the next quarter and whether profit, margins, expenses, and EPS changed. The supplied information does not establish an expected result, so no conclusion about growth or profitability can be made before the formal filing.

For the hospital sector, quarterly updates are useful for tracking the relationship between revenue, operating expenses, EBITDA, depreciation, interest costs, and net profit. In Asarfi Hospital's June-quarter table, expenses were 38, EBITDA was 10, depreciation was 3, interest was 1, and profit before tax was 6. These line items will be relevant when the September-quarter statement is released.

The scheduled board review also completes the immediate reporting sequence after the September AGM and the approval of FY26 accounts. The eventual filing should clarify whether the company reports standalone and consolidated numbers for the period, along with the statutory auditors' limited review conclusion.

Conclusion

Asarfi Hospital is scheduled to review and approve its unaudited September-quarter financial results on November 13, 2026. The most recent stated Q1 FY27 performance was revenue of ₹48.10 crore and profit of ₹4.27 crore, while a separate summary cited ₹47.53 crore of revenue and stated quarter-on-quarter and year-on-year growth rates.

The next item to watch is the company’s formal BSE filing after the board meeting, particularly the reported revenue, net profit, EBITDA, margin, EPS, and limited review report for the quarter ended September 30, 2026. Investors can also monitor progress on the approved BSE Main Board migration and NSE listing authorisation.